Gilead's first quarter 2026 revenue of $7.0B beat estimates, driven by 10% growth in its HIV franchise.

Gilead reported first quarter revenue of $7.0 billion and non-GAAP EPS of $2.03, beating analyst estimates. Results were driven by strong growth in the HIV and Oncology segments, which was partially offset by an expected decline in Veklury sales and competitive headwinds in Cell Therapy.

Key Highlights

• Product sales excluding Veklury grew 8% year-over-year to $6.8 billion, demonstrating the strength of the core business.
• The HIV franchise remains the primary growth driver, with sales increasing 10% to $5.0 billion, led by Biktarvy sales of $3.4 billion.
• The Oncology portfolio showed mixed results, with Trodelvy sales increasing 37% to $402 million, while Cell Therapy sales decreased 12% to $407 million.
• Gilead raised its full-year 2026 product sales guidance but lowered its EPS guidance to reflect an anticipated $11.5 billion in IPR&D charges related to recent acquisitions.